Comparison of Emergence and Oxygenation During One-lung Ventilation With Desflurane and Propofol Anesthesia

NCT02324283 | Active Not Recruiting Results

• 1 other identifier: 12-97
• Study Type: interventional
• Target: 80
• Locations: 1 country
• Sites: 1

Brief Summary

Which is more adequate general anesthetic agent, desflurane or propofol, for emergence and recovery time, and perioperative oxygenation in lung resection surgery?

Conditions

Lung Cancer

Keywords

one-lung ventilation, oxygenation

Outcome Measures

Primary Outcomes (1)

• Oxygenation

  Arterial blood gases are monitored.Pulmonary blood flow is measured using transesophageal echocardiogram.

  prior to surgery to one-hour after extubation

Secondary Outcomes (3)

• Rapidity of Emergence From Anesthesia

  one minute after cessation of anethetic agents to one hour after extubation

• Quality of Consiousness

  after extubation

• Postoperative Nausea and Vomiting

  on the postoperative day 1

Study Arms (2)

Desflurane

ACTIVE COMPARATOR

Desflurane group: this group of patients receives desflurane as the main anesthetic agent in addition to remifentanil infusion at 0.1\~0.3 mcg/kg/min during one-lung anesthesia. Bispectral index will be maintained between 45 and 50. Arterial blood gases and pulmonary blood flow by using tansesphageal echocardiogrphy will be measured.

Drug: desflurane

Propofol

ACTIVE COMPARATOR

Propofol group: this group of patients receives propofol as the main anesthetic agent in addition to remifentanil infusion at the rate of 0.1\~0.3 mcg./g/min during one-lung anesthesia. Bispectral index will be maintained between 45 and 50. Arterial blood gases and pulmonary blood flow by using tansesphageal echocardiogrphy will be measured.

Drug: propofol

Interventions

desflurane DRUG

Desflurane group: this group of patients receives desflurane as the main anesthetic agent during one-lung anesthesia. Propofol group: this group of patients receives propofol as the main anesthetic agnet during on-lung anesthesia.

Also known as: Suprene

Desflurane

propofol DRUG

Propofol group:this group of patients receives propofol as the main anesthetic agent during one-lung anesthesia.

Also known as: Diprivan

Propofol

Eligibility Criteria

• Age: 20 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients agree to participate in the study
• Patients undergoing lung cancer surgery requiring one-lung ventilation.
• American Society of Anesthesiologists Physical Status Class 1 or 2

You may not qualify if:

• Patients with any of the following will be excluded from lung cancer patients.
• New York Heart Association Classification more than 2
• Respiratory dysfunction Vital Capacity or percent predicted Forced expiratory volume in one second is less than 50 %
• Pulmonary hypertension with mean pulmonary arterial pressure more than 30 mmHg
• Coagulation dysfunction
• The administration of steroids and immunosuppressive agents within 3 months prior to surgery
• Infection with active inflammation
• Pneumonectomy patients
• Cases of epidural anesthesia is contraindicated

Sponsors & Collaborators

• Juntendo University: lead
• Baxter Healthcare Corporation: collaborator

Study Sites (1)

University of Juntendo

Bunkyō City, Tokyko, 113-8421, Japan

Location

MeSH Terms

Conditions

Lung Neoplasms

Interventions

Desflurane; Propofol

Condition Hierarchy (Ancestors)

Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases

Intervention Hierarchy (Ancestors)

Ethyl Ethers; Ethers; Organic Chemicals; Methyl Ethers; Hydrocarbons, Fluorinated; Hydrocarbons, Halogenated; Hydrocarbons; Phenols; Benzene Derivatives; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic

Results Point of Contact

• Title: Dr. Izumi Kawagoe
• Organization: Juntendo University

ikawago@juntendo.ac.jp

+81338133111

Study Officials

• Eiichi Inada, M.D.

  Juntendo University

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: PARTICIPANT
• Purpose: OTHER
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 15, 2014
• First Posted: December 24, 2014
• Study Start: October 1, 2012
• Primary Completion: June 1, 2016
• Study Completion: December 1, 2024
• Last Updated: April 5, 2024
• Results First Posted: April 5, 2024

Record last verified: 2024-04

Locations

JP (1)